Implant Sciences Receives Final Listing Determination Letter

WILMINGTON, Mass.--(Business Wire)--
Implant Sciences Corporation (NYSE Amex: IMX), a supplier of systems and sensors
for the homeland security market and related industries, today announced that it
received notice from the staff of the Corporate Compliance department of the
NYSE Regulation Inc. on behalf of NYSE Amex of its determination to prohibit the
continued listing of the Company`s common stock on the Exchange and to initiate
delisting proceedings. Implant Sciences has filed its notice to appeal this
decision.

Pending the outcome of its appeal, the Company will attempt to ensure that its
common stock is quoted and eligible for trading on the Over-The-Counter Bulletin
Board (the "OTCBB"), a regulated electronic quotation service offered by the
Financial Industry Regulatory Authority, Inc. (FINRA), on or before the date on
which trading is suspended by the Exchange, or as soon as practicable
thereafter. Companies listed on this exchange are fully reporting companies.

The Staff determined, as previously disclosed, that the Company was not in
compliance with Sections 1003(a)(i), (ii), (iii) and (iv) of the Exchange`s
Company Guide.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and
systems for the Security, Safety and Defense (SS&D) industries. The Company has
developed proprietary technologies used in its commercial portable and bench-top
explosive trace detection systems which ship to a growing number of locations
domestically and internationally. For further details on the Company and its
products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that
term is defined in the Private Securities Litigation Reform Act of 1995. Such
statements are based on management's current expectations and are subject to
risks and uncertainties that could cause the Company's actual results to differ
materially from the forward-looking statements. Such risks and uncertainties
include, but are not limited to, the risks that: if the NYSE Amex delists our
common stock, it may be extremely difficult to raise capital; if third party
credit is unavailable, our working capital could be restricted and we may not be
able to borrow capital; and other risks and uncertainties described in the
Company's filings with the Securities and Exchange Commission, including its
most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's
current expectations and assumptions which could differ materially from the
forward-looking statements.

Implant Sciences Corporation
Glenn Bolduc, CEO, 978-752-1700
gbolduc@implantsciences.com

Copyright Business Wire 2009